The epidermal growth factor receptor (EGFR) is normally activated by ligand-induced dimerization. Oncogenic mutations in EGFR promote activation in a largely ligand-independent manner. Shan et al. uncover a partially disordered state of EGFR kinase, providing evidence that oncogenic mutations counteract this intrinsic structural instability to promote dimerization and aberrant activation.
Epidermal growth factor receptor (EGFR, also called ERBB1 or HER1) is a receptor tyrosine kinase that, upon binding of extracellular epidermal growth factor (EGF) proteins, dimerizes, stimulating its intrinsic tyrosine kinase activity. Overexpression, amplification, and mutation of EGFR occur in a wide range of human epithelial cancers. Gain-of-function mutations are found in a subset of non-small cell lung cancers (NSCLC), especially those of nonsmoking patients of East Asian heritage, whose tumors often exhibit a bronchoalveolar histology (Sharma et al., 2007) and respond to small molecule EGFR inhibitors. A truncated form of EGFR (EGFRvIII) is associated with tumorigenicity in experimental models and poor clinical prognosis of highgrade glioblastomas. Tumors that harbor EGFRvIII do not respond to approved small molecule EGFR inhibitors and may also provide a mechanism of drug resistance in other cancers (Sok et al., 2006) . Indeed, recent work suggests that compensatory EGFR activity contributes to resistance to small molecule inhibitors of oncogenic alleles of BRAF (Corcoran et al., 2012; Prahallad et al., 2012) , which can be reversed by coextinction of EGFR and BRAF signaling. Given the clear role of EGFR in the pathogenesis of cancer and the increasingly widespread use of EGFR inhibitors in the clinic, understanding the molecular details of EGFR function will inform the development of improved strategies to inhibit EGFR signaling.
Considerable structural work during the past decade has identified two conformations of the EGFR kinase domain: an active conformation that is similar to other active protein kinases and an inactive state that is reminiscent of an inactive conformation observed in Src family kinases and CDK2 (Stamos et al., 2002; Wood et al., 2004; Figure 1, left) . In EGFR signaling, ligand-induced dimerization of the extracellular portion of the receptor drives formation of an asymmetric interaction between the intracellular kinase domains in which the C lobe of the ''activator'' kinase domain binds to the N lobe of the ''receiver'' kinase domain (Zhang et al., 2006; Figure 1, right) . This regulatory scheme is short circuited by oncogenic mutations, which include various point substitutions, insertions, and deletions (Sharma et al., 2007) .
In this issue of Cell, Shan and colleagues use long-timescale molecular dynamics to interrogate EGFR kinase activation (Shan et al., 2012) . Recent advances in both simulation algorithms and purpose-built computing hardware enable microsecond to millisecond simulations of protein dynamics (Shaw et al., 2010) . Such simulations allow molecular voyeurs to ''watch'' proteins over timescales in which physiologically important conformational changes typically occur. In this study, the authors perform a series of EGFR simulations starting from crystal structures of both active and inactive conformations. This new data suggests that the kinase spends much of its time in a third state characterized by partial disorder (Figure 1 , middle). The simulations also suggest that one particular cancer-causing point mutation effectively locks the kinase into the active conformation, preventing it from adopting this flexible, limbo-like state.
Multiple pieces of evidence point to this unanticipated flexible yet inactive state. The authors simulate binding between EGFR and two inhibitors, gefitinib and lapatinib, that are currently deployed in the clinic. Gefitinib and the structurally similar drug erlotinib are used for treatment of EGFR mutant lung cancers, whereas lapatinib, a potent inhibitor of both EGFR and Her2 receptor tyrosine kinases, is used for treatment of Her2-driven breast cancers. Both are reversible, ATP-competitive inhibitors. Gefitinib can prevent ATP binding regardless of whether the kinase is in the active or inactive conformation. On the other hand, lapatinib can only bind the inactive conformation of the kinase. Its efficacy is ascribed in part to its very slow off rate from the enzyme, corresponding to a half-life of 300 min for the enzyme/ inhibitor complex (Wood et al., 2004) . Reassuringly, the simulations recapitulate the binding modes observed in crystal structures. Despite this same end result, the lapatinib simulations suggest that the compound can find its binding site in a much shorter time than previously suspected. As the authors note, a possible explanation for this discrepancy is that the slow experimentally deduced on rate arises from a rate-limiting transition from an alternate conformation that is not accessed in the simulation. This alternate conformation cannot be the active conformation because the wild-type enzyme has low catalytic activity in the absence of activating dimer interactions.
The authors also perform simulations starting in the active conformation, revealing an unexpectedly rapid transition (100 ns) to a prime candidate for this third state. Although this conformation exhibits one of the key features of the inactive state-an outwardly rotated C helix-other structural features of the kinase are unique. In particular, the C helix and surrounding regions, which are part of the ''receiver'' interface in the asymmetric dimer, appear disordered. A comparative simulation with the Src kinase reveals that its active conformation was stable in the course of 10 microsecond simulations. An experimental correlate for this result, hydrogen-deuterium exchange rates, shows that the C helix and adjacent N lobe surfaces of EGFR are markedly more dynamic than the corresponding regions of Src. The correlation between the simulation results and the relative disorder implied by the HDexchange rates supports a third conformational state for EGFR.
By examining simulations of the oncogenic L834R mutant, the authors find that it remains locked in the active conformation nearly 300 times longer than the wild-type kinase. Strikingly, the simulations position the mutant arginine residue to form salt bridge interactions with a series of negatively charged residues, including two key active site residues, Asp 831 and Asp 813. The authors propose that these salt bridge interactions directly stabilize the active conformation. Curiously, the interactions of L834R revealed by the simulation are not observed in crystal structures of this mutant, which show the arginine extending toward the backbone carbonyl of Arg812 (Yun et al., 2007) . It is unclear whether the salt bridge interactions suggested by the simulation are completely compatible with the full catalytic activity, as the orientation of Asp813 would likely be altered by these interactions, potentially compromising its ability to function as the catalytic base. Interestingly, the authors show that simulations of other activating mutants, including an exon19 deletion and the G795S, L837Q, and S744I point mutations, all appear to stabilize the active state at the expense of the disordered intermediate.
Shan and colleagues reason that stabilization of the active conformation should promote dimerization, and with biochemical and enzymatic measurements, they show that the L834R mutant favors dimer formation. Although these data are consistent with the authors' conclusions, they are also consistent with previous results suggesting that the L834R mutation favors EGFR dimerization by destabilizing the inactive conformation (Yun et al., 2007) . Irrespective of mechanism, the dependence of L834R and perhaps other mutants on dimerization for full catalytic activation provides a solid rationale for further exploration of combination therapy with inhibitors of dimerization, such as the EGFR antibody cetuximab. New therapeutic strategies for EGFR-driven cancers could also target the intracellular dimerization interface. (red) is displaced from the active site (left) and an active state in which the inward, active position of the C helix is stabilized by binding of an ''activator'' kinase in the context of an asymmetric dimer (right). The transition from inactive to active brings Glu 738 of the C helix into the active site, where it forms a key salt bridge with Lys 722 and rearranges the kinase activation loop (A loop, orange). Using molecular dynamics simulations, Shan et al. find that the active conformation is unstable in the absence of the activator kinase and that it rapidly collapses into a partially disordered state (center) characterized by a largely unstructured but outwardly rotated C helix (pink coil surface). Simulations with a number of lung-cancer-inducing mutations, including the L834R point mutation, show that these mutations tend to stabilize the active conformation in the absence of the activating dimer interaction.
The new work from Shan and colleagues demonstrates the expanding reach of molecular dynamics simulations and sets the stage for future investigations of EGFR regulation, its oncogenic activation, and inhibitor binding properties. For example, it will be interesting to know what effect inclusion of Mg 2+ and ATP in the molecular dynamics calculations has on the observed conformational rearrangements. Additionally, the present simulations do not reveal the transition to the inactive conformation targeted by lapatinib. Though it may be no small matter to extend the simulation timescale sufficiently to observe this transition, it will be of interest to computationally characterize the relative stability of the active, disordered, and fully inactive states.
This study also provides a few testable hypotheses that may move the field forward. For instance, if different activating mutations stabilize the active state via distinct mechanisms, one might expect that, in combination, they would yield higher levels of activity, further shifting the equilibrium toward dimerization. Finally, the prediction that phosphorylation of Tyr845 in the EGFR activation loop activates the kinase and stabilizes the EGFR dimer may motivate the field to reexamine the role of this phosphorylation event in EGFR signaling.
Geneticists have long sought to identify the genetic changes that made us human, but pinpointing the functionally relevant changes has been challenging. Two papers in this issue suggest that partial duplication of SRGAP2, producing an incomplete protein that antagonizes the original, contributed to human brain evolution.
Humans differ from the other great apes in many ways, one of the more obvious being our larger, more complex brains. These human-specific characteristics have evolved in the last 6-7 million years since we split from our common ancestor with chimpanzees and bonobos. We can catalog the phenotypic differences between humans and other great apes, and in some cases, we can determine when they evolved, using evidence in the fossil record. Brain size increased throughout this period, although unevenly ( Figure 1A and 1B) , but fossil details of internal brain structure are sparse. In a complementary way, we can catalog the genetic differences between humans and chimpanzees from their genome sequences (Chimpanzee Sequencing and Analysis Consortium, 2005) and identify which differences arose on the human lineage by comparison with an outgroup-a species external to the chimpanzee-human branch, such as gorilla (Scally et al., 2012) . But there are around 20 million genetic changes that are specific to humans, most of which probably have no functional impact whatsoever. How do we pick out the few functionally relevant changes and link them to their phenotypic consequences? Two papers in this issue of Cell now show one way that this can be accomplished
